Abstract
Recombinant human erythropoietin (rHuEPO) administration has been associated with an increased risk of hypertension and thrombosis in uremic patients. rHuEPO and endothelial cells cultured in an uremic environment. Results indicate that rHuEPO does not exert an additional activating effect to that caused by the uremic media per se.Figures & Tables
Article Information
Published
2002-01-01
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
Article Usage
Online Views
333
PDF Downloads
180
No Data